Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Google Secures Pentagon AI Deal for Classified Projects 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
T-Mobile Beats Q1 Earnings Expectations on Strong Postpaid Growth 
TSMC Exits Arm Holdings with $231 Million Share Sale Amid Strategic Portfolio Shift 
Why Paycom Was Named a 2026 Platinum Employer on the Where You Work Matters List 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Brazil Pension Fund Crackdown After Banco Master Collapse Raises Investment Concerns 
Taiwan Court Fines Tokyo Electron Unit $4.78M in Major TSMC Trade Secrets Case 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Robinhood Q1 Earnings Miss Expectations, Stock Drops After Hours 
CAMBRIDGE, Mass., May 04, 2017 -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced its first quarter 2017 financial results and corporate highlights conference call and live webcast scheduled for Tuesday, May 9, 2017 at 5:30 p.m. EDT.
The live call may be accessed by dialing (877) 851-3834 for domestic callers or +1 (631) 291-4595 for international callers, and referencing conference ID number 18530851. A live audio webcast of the conference call will be available online from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. The webcast will be archived for 30 days.
About Voyager Therapeutics
Voyager Therapeutics is a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the CNS. Voyager is committed to advancing the field of AAV gene therapy through innovation and investment in vector engineering and optimization, manufacturing and dosing and delivery techniques. The Company’s pipeline focuses on severe CNS diseases in need of effective new therapies, including advanced Parkinson’s disease, a monogenic form of ALS, Huntington’s disease, Friedreich’s ataxia, frontotemporal dementia, Alzheimer’s disease and severe, chronic pain. Voyager has broad strategic collaborations with Sanofi Genzyme, the specialty care global business unit of Sanofi, and the University of Massachusetts Medical School. Founded by scientific and clinical leaders in the fields of AAV gene therapy, expressed RNA interference and neuroscience, Voyager Therapeutics is headquartered in Cambridge, Massachusetts. For more information, please visit www.voyagertherapeutics.com. Follow Voyager on LinkedIn.
Investor Relations: Matt Osborne Head of Investor Relations & Corporate Communications 857-259-5353 [email protected] Media: Katie Engleman Pure Communications, Inc. 910-509-3977 [email protected]
